Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +33.64%
#3 Cysic Cysic +25.00%
#4 Nockchain Nockchain +18.92%
#5 Velvet Velvet +18.00%
#6 Perle Perle +14.46%
#7 FOLKS FOLKS +13.61%
#8 Nillion Nillion +12.50%
#9 Versatize Coin Versatize Coin +12.49%
#10 Starpower Starpower +10.78%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Medesis Pharma S.A. Medesis Pharma S.A.

Medesis Pharma S.A.

ALMDP
Rank in Stocks #37493
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development... Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
Share Price
$0.38207938
Last synced: 2025-04-07
Market Cap
$1.67M
Change (1 day)
-0.39%
Change (1 year)
0.00%
Country
FR
Trade Medesis Pharma S.A. (ALMDP)

Category

Healthcare
P/E ratio for Medesis Pharma S.A. (ALMDP)
P/E ratio as of 2026 TTM: 0
According to Medesis Pharma S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Medesis Pharma S.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.